The American Diabetes Association updated its treatment guidelines to include Amarin’s Vascepa for patients with diabetes and cardiovascular disease, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the addition as an incremental positive that should help drive Vascepa sales in 2019. Further, Q1 scripts suggest Vascepa sales of $80M-$85M, above the consensus estimate of $67M, Yee says. He keeps a Buy rating on Amarin with a $30 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.